This work was supported by the National Natural Science Foundation of China (NO.81860413, 81960455), Yunnan Science and Technology Department Fund (202001AY070001-080), Scientific Research Foundation of Education Department of Yunnan Province(2019J1274).

The research was approved by the medical ethics committee of Yunnan Cancer Hospital/the Third Affiliated Hospital of Kunming Medical University. All the subjects/legal guardians signed informed consent.
1. Slide preparation
<ol>
	<li>Cut sections of paired paraffin blocks containing primary lung tumor or lung cancer brain metastases cells at a thickness of 4 &#181;m using a microtome. Remove sections to water and separate with tweezers, choose the best one and adhere it onto...

In Situ Immunohistochemical Detection of Immune Cell Markers in Cancer Tissues

<ol>
	<li>Wanleenuwat, P., Iwanowski, P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Metastases+to+the+central+nervous+system:+Molecular+basis+and+clinical+considerations.">Metastases to the central nervous system: Molecular basis and clinical considerations.</a> J Neurol Sci. 412, 116755 (2020).</li><li>Schoenmaekers, J., Dingemans, A. C., Hendriks, L. E. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Brain+imaging+in+early+stage+non-small+cell+lung+cancer:+still+a+controversial+topic.">Brain imaging in early stage non-small cell lung cancer: still a controversial topic.</a> J Thorac Dis. 10, S2168-S2171 (2018).</li><li>Vilari&#241;o, N., Bruna, J., Bosch-Barrera, J., Valiente, M., Nadal, E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Immunotherapy+in+NSCLC+patients+with+brain+metastases.+Understanding+brain+tumor+microenvironment+and+dissecting+outcomes+from+immune+checkpoint+blockade+in+the+clinic.">Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.</a> Cancer Treat Rev. 89, 102067 (2020).</li><li>Babar, Q., Saeed, A., Tabish, T. A., Sarwar, M., Thorat, N. D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Targeting+the+tumor+microenvironment:+Potential+strategy+for+cancer+therapeutics.">Targeting the tumor microenvironment: Potential strategy for cancer therapeutics.</a> Biochim Biophys Acta Mol Basis Dis. 1869 (6), 166746 (2023).</li><li>Goldberg, S. B., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Pembrolizumab+for+management+of+patients+with+NSCLC+and+brain+metastases:+long-term+results+and+biomarker+analysis+from+a+non-randomised,+open-label,+phase+2+trial.">Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.</a> Lancet Oncol. 21 (5), 655-663 (2020).</li><li>Sukswai, N., Khoury, J. D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Immunohistochemistry+Innovations+for+Diagnosis+and+Tissue-Based+Biomarker+Detection.">Immunohistochemistry Innovations for Diagnosis and Tissue-Based Biomarker Detection.</a> Curr Hematol Malig Rep. 14 (5), 368-375 (2019).</li><li>Janardhan, K. S., Jensen, H., Clayton, N. P., Herbert, R. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Immunohistochemistry+in+Investigative+and+Toxicologic+Pathology.">Immunohistochemistry in Investigative and Toxicologic Pathology.</a> Toxicol Pathol. 46 (5), 488-510 (2018).</li><li>Torlakovic, E. E., Nielsen, S., Vyberg, M., Taylor, C. R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Getting+controls+under+control:+the+time+is+now+for+immunohistochemistry.">Getting controls under control: the time is now for immunohistochemistry.</a> J Clin Pathol. 68 (11), 879-882 (2015).</li><li>Tan, W. C. C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Overview+of+multiplex+immunohistochemistry/immunofluorescence+techniques+in+the+era+of+cancer+immunotherapy.">Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy.</a> Cancer Commun (Lond). 40 (4), 135-153 (2020).</li><li>Wong, P. F., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Multiplex+quantitative+analysis+of+tumor-infiltrating+lymphocytes+and+immunotherapy+outcome+in+metastatic+melanoma.">Multiplex quantitative analysis of tumor-infiltrating lymphocytes and immunotherapy outcome in metastatic melanoma.</a> Clin Cancer Res. 25 (8), 2442-2449 (2019).</li><li>Sanchez, K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Multiplex+immunofluorescence+to+measure+dynamic+changes+in+tumor-infiltrating+lymphocytes+and+PD-L1+in+early-stage+breast+cancer.">Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer.</a> Breast Cancer Res. 23 (1), 2 (2021).</li><li>Zhang, W., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Multiplex+immunohistochemistry+indicates+biomarkers+in+colorectal+cancer.">Multiplex immunohistochemistry indicates biomarkers in colorectal cancer.</a> Neoplasma. 68 (6), 1272-1282 (2021).</li><li>Salameh, S., Nouel, D., Flores, C., Hoops, D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=An+optimized+immunohistochemistry+protocol+for+detecting+the+guidance+cue+Netrin-1+in+neural+tissue.">An optimized immunohistochemistry protocol for detecting the guidance cue Netrin-1 in neural tissue.</a> MethodsX. 5, 1-7 (2018).</li><li>McClellan, P., Jacquet, R., Yu, Q., Landis, W. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+Method+for+the+immunohistochemical+identification+and+localization+of+Osterix+in+periosteum-wrapped+constructs+for+tissue+engineering+of+bone.">A Method for the immunohistochemical identification and localization of Osterix in periosteum-wrapped constructs for tissue engineering of bone.</a> J Histochem Cytochem. 65 (7), 407-420 (2017).</li><li>Sun, Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Sudan+black+B+reduces+autofluorescence+in+murine+renal+tissue.">Sudan black B reduces autofluorescence in murine renal tissue.</a> Arch Pathol Lab Med. 135 (10), 1335-1342 (2011).</li><li>Taube, J. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+Society+for+Immunotherapy+of+Cancer+statement+on+best+practices+for+multiplex+immunohistochemistry+(IHC)+and+immunofluorescence+(IF)+staining+and+validation.">The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation.</a> J Immunother Cancer. 8 (1), 000155 (2020).</li><li>Clarke, G. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+novel,+automated+technology+for+multiplex+biomarker+imaging+and+application+to+breast+cancer.">A novel, automated technology for multiplex biomarker imaging and application to breast cancer.</a> Histopathology. 64 (2), 242-255 (2014).</li><li>Oliveira, V. C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Sudan+Black+B+treatment+reduces+autofluorescence+and+improves+resolution+of+in+situ+hybridization+specific+fluorescent+signals+of+brain+sections.">Sudan Black B treatment reduces autofluorescence and improves resolution of in situ hybridization specific fluorescent signals of brain sections.</a> Histol Histopathol. 25 (8), 1017-1024 (2010).</li><li>Ahrens, M. J., Dudley, A. T. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Chemical+pretreatment+of+growth+plate+cartilage+increases+immunofluorescence+sensitivity.">Chemical pretreatment of growth plate cartilage increases immunofluorescence sensitivity.</a> J Histochem Cytochem. 59 (4), 408-418 (2011).</li><li>Zhang, Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Spectral+characteristics+of+autofluorescence+in+renal+tissue+and+methods+for+reducing+fluorescence+background+in+confocal+laser+scanning+microscopy.">Spectral characteristics of autofluorescence in renal tissue and methods for reducing fluorescence background in confocal laser scanning microscopy.</a> J Fluoresc. 28 (2), 561-572 (2018).</li></ol>

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

We have described the process for multiplex cyclic fluorescence immunohistochemistry staining. The primary antibody selection is a crucial aspect of the fluorescence immunohistochemistry assay, and monoclonal antibodies are recommended for better specificity and repeatability. To optimize the working concentration of the primary antibody, a series of dilutions have been tested through immunohistochemistry experiments. Both positive controls (to assess target antigen expression) and negative controls (no primary antibody ...

Brain metastases (BM) represent the most common central nervous system (CNS) tumors, occurring in nearly half of non-small cell lung cancer cases (NSCLC), with a poor prognosis1. An estimated 10%-20% of NSCLC patients already have BM at the time of initial diagnosis, and approximately 40% of NSCLC cases will develop BM during the course of treatment2. The tumor microenvironment (TME) is closely associated with NSCLC occurrence and BM, including various components, such as blood vessels, fibroblasts, macrophages, extracellular matrix (ECM), lymphoid, bone marrow-derived immune cells, and signaling molecules3,4. Microenvironmental immune cells play a crucial role in influencing cancer cell growth and development. Brain metastases present numerous potential treatment targets characterized by complex immunological microenvironments and signaling processes. For instance, PD-1 inhibitors have shown clinical efficacy for patients with lung cancer brain metastasis (LCBM) as an immune-checkpoint inhibitor (ICI). However, the frequency of responses to PD-1 therapy varies between primary NSCLC and LCBM5, suggesting that the tumor immune microenvironment acts as a critical ICI regulator.
Immunohistochemistry (IHC) is an invaluable tool in the fields of biology, foundation medicine, and pathology6. This detection method visualizes antigen expression through the interaction of antigen-antibody on a tissue slide7. IHC is used for diagnosing predictive markers, evaluating prognostic markers, guiding targeted therapies, and exploring the biological functions of tumor cells8. However, the traditional IHC method can only detect one biomarker at a time. To address this limitation, the innovation of immunohistochemical technology has led to the development of multiplex fluorescence immunohistochemistry (mfIHC), which allows for the simultaneous identification of multiple protein markers on the same tissue slide, both in bright field and fluorescent field9. This advancement provides accurate analysis of cell composition and molecular interactions among stromal cells, immune cells, and cancer cells within the TME.
In this study, we present a protocol for multiplex cyclic immunohistochemistry to analyze the spatial distribution of immune cells. Two primary antibodies of different species, such as rabbit and rat, are chosen for incubation simultaneously, followed by fluorescence-labeled secondary antibodies. Antigen retrieval is performed after each round of antigen-antibody reaction. Autofluorescence is blocked, and 4', 6-diamidino-2-phenylindole (DAPI) is used for staining the nuclei. The panel includes sequential detection of CD3, CD8, CD20, and CK, cells are categorized according to the markers: tumor cells (CK+), mature T cells (CD3+), cytotoxic T cells (CD3+CD8+), B cells (CD20+)10,11.

<table border="1" fo:keep-together.within-page="1" fo:keep-with-next.within-page="always">
	<tbody>
		<tr>
			<td>0.15 mol/L KmnO4</td>
			<td>Maixin Biotechnology Co. Ltd.</td>
			<td>MST-8005</td>
			<td></td>
		</tr>
		<tr>
			<td>100x sodium citrate&#160;</td>
			<td>Maixin Biotechnology Co., Ltd</td>
			<td>MVS-0100</td>
			<td></td>
		</tr>
		<tr>
			<td>3% hydrogen peroxide</td>
			<td>Maixin Biotechnology Co., Ltd</td>
			<td>SP KIT-A1</td>
			<td></td>
		</tr>
		<tr>
			<td>3D Pannoramic MIDI</td>
			<td>3D histech Ltd</td>
			<td>Pannoramic MIDI 1.18</td>
			<td></td>
		</tr>
		<tr>
			<td>Alexa Fluor 488</td>
			<td>Abcam</td>
			<td>ab150113</td>
			<td></td>
		</tr>
		<tr>
			<td>Alexa Fluor 568&#160;</td>
			<td>Abcam</td>
			<td>ab175701</td>
			<td></td>
		</tr>
		<tr>
			<td>Alexa Fluor 594</td>
			<td>Abcam</td>
			<td>ab150116</td>
			<td></td>
		</tr>
		<tr>
			<td>Alexa Fluor 647</td>
			<td>Abcam</td>
			<td>ab150079</td>
			<td></td>
		</tr>
		<tr>
			<td>Bond primary antibody diluent</td>
			<td>Lecia</td>
			<td>AR9352</td>
			<td></td>
		</tr>
		<tr>
			<td>CD20</td>
			<td>Maixin Biotechnology Co., Ltd</td>
			<td>kit-0001</td>
			<td></td>
		</tr>
		<tr>
			<td>CD3</td>
			<td>Maixin Biotechnology Co., Ltd.</td>
			<td>&#160;kit-0003</td>
			<td></td>
		</tr>
		<tr>
			<td>CD8&#160;</td>
			<td>Maixin Biotechnology Co., Ltd</td>
			<td>RMA-0514</td>
			<td></td>
		</tr>
		<tr>
			<td>CK</td>
			<td>Maixin Biotechnology Co. Ltd.</td>
			<td>MAB-0671,</td>
			<td></td>
		</tr>
		<tr>
			<td>DAPI</td>
			<td>sig-ma</td>
			<td>D8417</td>
			<td></td>
		</tr>
		<tr>
			<td>ethanol</td>
			<td>Sinopharm Group Chemical reagent Co., LTD</td>
			<td>10009218</td>
			<td></td>
		</tr>
		<tr>
			<td>Histocore Multicut</td>
			<td>lecia</td>
			<td>2245</td>
			<td></td>
		</tr>
		<tr>
			<td>PBS(powder)</td>
			<td>Maixin Biotechnology Co., Ltd</td>
			<td>PBS-0061</td>
			<td></td>
		</tr>
		<tr>
			<td>slide viwer&#160;</td>
			<td>3D histech Ltd</td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>xylene</td>
			<td>Sinopharm Group Chemical reagent Co., LTD</td>
			<td>10023418</td>
			<td></td>
		</tr>
	</tbody>
</table>

multiplex cyclic fluorescent immunohistochemistry

The tumor microenvironment involves interactions between host cells, tumor cells, immune cells, stromal cells, and vasculature. Characterizing and spatially organizing immune cell subsets and target proteins are crucial for prognostic and therapeutic purposes. This has led to the development of multiplexed immunohistochemistry staining methods. Multiplex fluorescence immunohistochemistry allows the simultaneous detection of multiple markers, facilitating a comprehensive understanding of cell function and intercellular interactions. In this paper, we describe a workflow for the multiplex cyclic fluorescent immunohistochemistry assay and its application in the quantification analysis of lymphocyte subsets. The multiplex cyclic fluorescent immunohistochemistry staining follows similar steps and reagents as standard immunohistochemistry, involving antigen retrieval, cyclic antibody incubation, and staining on a formalin-fixed paraffin-embedded (FFPE) tissue slide. During the antigen-antibody reaction, a mixture of antibodies from different species is prepared. Conditions, such as antigen retrieval time and antibody concentration, are optimized and validated to increase the signal-to-noise ratio. This technique is reproducible and serves as a valuable tool for immunotherapy research and clinical applications.

Author Spotlight: Efficient Detection of Immune Cell-Infiltration in Cancer Tissues Using Fluorescent Immunohistochemistry

Multiplex Cyclic Fluorescent Immunohistochemistry

The challenge for immunohistochemistry is to choose the species of primary and secondary monoclonal antibodies to avoid cross-reactivity and obtain better specificity and repeatability. Gender decision is necessary to optimize the antibody dilution ratio. Meanwhile, another challenge is to align the localization of and the sub structures.The use of this protocol meet the technical evolution of the distribution of three lymphocytic subpopulations, such as CT three, positive CT three, and CT eight positive and CT 20 positive based on in cell counts and the protein expression in conserv tissues, the level of infiltration can be observed too. In our protocol, the parameter Antibodies and the Fluor secondary antibodies derive from different species at the iso mixture making us a efficient. This measure also shows a specific measure between antibody and antigen.

We present a protocol for cyclic antigen detection using 5-color multiplex fluorescence on a single slide. Through our optimization of the assay, we enable the incubation of two antibodies from different species (Figure 1). The necessary devices for the experiment procedure include a pressure cooker and immunostaining box (Figure 2A).
After completing the assay, we define pseudo color of the four markers before scanning the slides. Th...

Watch this Scientific Journal Video about Author Spotlight: Efficient Detection of Immune Cell-Infiltration in Cancer Tissues Using Fluorescent Immunohistochemistry at JoVE.com

Multiplex cyclic immunohistochemistry allows in situ detection of multiple markers simultaneously using repeated antigen-antibody incubation, image scanning, and image alignment and integration. Here, we present the operating protocol for identifying immune cell substrates with this technology in lung cancer and paired brain metastasis samples.

The tumor microenvironment involves interactions between host cells, tumor cells, immune cells, stromal cells, and vasculature. Characterizing and ...

multiplex-cyclic-fluorescent-immunohistochemistry

Research

JoVE Journal

Cancer Research

Preparation of Slides for Multiplex Cyclic Immunohistochemistry of Cancer Tissue Sections

Multiplex Cyclic Fluorescent Immunohistochemical Staining of Cancer Tissue Sections

395 Views.  The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Hospital.  Multiplex cyclic immunohistochemistry allows in situ detection of multiple markers simultaneously using repeated antigen-antibody incubation, image scanning, and image alignment and integration. Here, we present the operating protocol for identifying immune cell substrates with this technology in lung cancer and paired brain metastasis samples.

In Situ Immunohistochemical Detection of Immune Cell Markers in Cancer Tissues

Summary